This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / PepGen Inc. Sued for Securities Violations
Regulatory class action lawsuit

PepGen Inc. Sued for Securities Violations

Analysis based on 9 articles · First reported Jun 12, 2025 · Last updated Jul 07, 2025

Sentiment
-40
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is impacted by the potential financial losses for PepGen Inc. due to the class action lawsuit, which alleges false and misleading statements about its product candidate. This event could lead to a decrease in PepGen's stock price and investor confidence.

Biotechnology Legal Services
Event Summary

The Gross Law Firm has issued multiple notices to shareholders of PepGen Inc. (NASDAQ: PEPG) regarding a class action lawsuit. The lawsuit alleges that PepGen made materially false and/or misleading statements between March 7, 2024, and March 3, 2025. Specifically, the complaint claims that PepGen's lead product candidate, PGN-EDO51, was less effective and safe than represented, and that its phase two CONNECT2 study was dangerous or otherwise deficient for United States — Food and Drug Administration approval. As a result, PepGen was likely to halt the CONNECT2 study, and the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated. Shareholders who purchased shares during the specified class period are encouraged to contact The Gross Law Firm to discuss possible lead plaintiff appointment, with a deadline of August 8, 2025.

Entities Involved
stock
PepGen
PepGen is being sued for allegedly issuing materially false and/or misleading statements regarding its lead product candidate, PGN-EDO51, and its CONNECT2 study, which could lead to financial losses for the company and its shareholders.
Importance 100.0 Sentiment -70.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
Relationships
PepGen related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.